Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies

被引：13

作者：

di Noia, Vincenzo ^{[1
]}

D'Argento, Ettore ^{[1
]}

Pilotto, Sara ^{[2
]}

Grizzi, Giulia ^{[2
]}

Caccese, Mario ^{[2
]}

Iacovelli, Roberto ^{[2
]}

Tortora, Giampaolo ^{[2
]}

Bria, Emilio ^{[1
]}

机构：

[1] Univ Cattolica Sacro Cuore, UOC Oncol Med, Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy

[2] Univ Verona, UOC Oncol, Dept Med, Azienda Osped Univ Integrata, Verona, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2018年 / 18卷 / 09期

关键词：

Necitumumab; EGFR; monoclonal antibody; squamous; NSCLC; CHEMOTHERAPY PLUS CETUXIMAB; GROWTH-FACTOR RECEPTOR; PHASE-III TRIAL; OPEN-LABEL; 1ST-LINE TREATMENT; EGFR-EXPRESSION; THERAPY; MULTICENTER; CISPLATIN; ANTIBODY;

D O I：

10.1080/14712598.2018.1508445

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Introduction: Over the last decade, epidermal growth factor receptor (EGFR) signaling was investigated as a potential target for tyrosine kinase inhibitors in the treatment of non-small-cell lung cancer (NSCLC). Necitumumab is a fully humanized IgG1 monoclonal antibody directed against the binding domain of EGFR, approved in combination with cisplatin-gemcitabine for the first-line treatment of squamous NSCLC.Areas covered: The purpose of this manuscript is to systematically review the state of the art of necitumumab for the treatment of metastatic NSCLC, focusing on predictive factors, cost-effectiveness, and future potential combinations with additional agents.Expert opinion: Despite recent therapeutic advances, platinum-based chemotherapy still represents the most widely used first-line treatment for advanced NSCLC, particularly for the squamous histotype. Necitumumab is nowadays the first targeted agent providing an (statistically significant) additional survival gain to squamous NSCLC patients when combined with first-line chemotherapy at the cost of an increased (although manageable) toxicity, as shown in the SQUIRE trial. Hopefully, improvement in patients' selection by identifying reliable predictive markers and the combination with new agents may help to maximize the benefit of this targeted treatment, which is currently limited by a not optimal cost-benefit ratio.

引用

页码：937 / 945

页数：9

共 55 条

[1]

[Anonymous], ANN ONCOL

[2]

[Anonymous], J CLIN ONCOL

[3] Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance [J].

Bagchi, Atrish ;

Haidar, Jaafar N. ;

Eastman, Scott W. ;

Vieth, Michal ;

Topper, Michael ;

Iacolina, Michelle D. ;

Walker, Jason M. ;

Forest, Amelie ;

Shen, Yang ;

Novosiadly, Ruslan D. ;

Ferguson, Kathryn M. .

MOLECULAR CANCER THERAPEUTICS, 2018, 17 (02) :521-531

[4] Fc Receptor-Dependent Mechanisms of Monoclonal Antibody Therapy of Cancer [J].

Bakema, Jantine E. ;

van Egmond, Marjolein .

FC RECEPTORS, 2014, 382 :373-392

[5] Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) [J].

Barlesi, Fabrice ;

Mazieres, Julien ;

Merlio, Jean-Philippe ;

Debieuvre, Didier ;

Mosser, Jean ;

Lena, Herve ;

Ouafik, L'Houcine ;

Besse, Benjamin ;

Rouquette, Isabelle ;

Westeel, Virginie ;

Escande, Fabienne ;

Monnet, Isabelle ;

Lemoine, Antoinette ;

Veillon, Remi ;

Blons, Helene ;

Audigier-Valette, Clarisse ;

Bringuier, Pierre-Paul ;

Lamy, Regine ;

Beau-Faller, Michele ;

Pujol, Jean-Louis ;

Sabourin, Jean-Christophe ;

Penault-Llorca, Frederique ;

Denis, Marc G. ;

Lantuejoul, Sylvie ;

Morin, Franck ;

Quan Tran ;

Missy, Pascale ;

Langlais, Alexandra ;

Milleron, Bernard ;

Cadranel, Jacques ;

Soria, Jean-Charles ;

Zalcman, Gerard .

LANCET, 2016, 387 (10026) :1415-1426

[6]

Besse B, 2017, ANN ONCOL, V28

[7] Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) [J].

Besse, Benjamin ;

Vansteenkiste, Johan ;

Renault, Patrick-Aldo ;

Frimodt-Moller, Bente ;

Chao, Grace ;

Gil, Maciej ;

Barlesi, Fabrice .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S1227-S1228

[8] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[9] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[10] Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis [J].

Bria, E. ;

Milella, M. ;

Cuppone, F. ;

Novello, S. ;

Ceribelli, A. ;

Vaccaro, V. ;

Sperduti, I. ;

Gelibter, A. ;

Scagliotti, G. V. ;

Cognetti, F. ;

Giannarelli, D. .

ANNALS OF ONCOLOGY, 2011, 22 (10) :2277-2285

← 1 2 3 4 5 6 →